<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750256</url>
  </required_header>
  <id_info>
    <org_study_id>PHX111427</org_study_id>
    <nct_id>NCT00750256</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-time in human study to investigate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of GSK1278863A in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2008</start_date>
  <completion_date type="Actual">December 12, 2008</completion_date>
  <primary_completion_date type="Actual">December 12, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GSK1278863A safety endpoints: adverse events reporting, clinical safety laboratory tests (hematology, chemistry, urinalysis,and fecal occult blood), vital signs, 12-lead ECG, dual-lead cardiac monitoring.</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood and urine levels of GSK1278863A</measure>
    <time_frame>2 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of GSK1278863A on hematological markers</measure>
    <time_frame>2 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1278863A</intervention_name>
    <description>GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.</description>
    <arm_group_label>Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking (within 40 days of screening), adult males and females between 18
             and 55 years of age, inclusive

          -  Female subjects are eligible for participation in the study if they are of:

          -  Non-childbearing potential (i.e., physiologically incapable of becoming pregnant);

          -  Male subjects agree to use contraception methods

          -  Body weight &gt; or = 50 kg; BMI: 19-31 kg/m2, inclusive

          -  Subject has a QTc &lt;450 msec or &lt;480 msec if associated with bundle branch block

          -  Subject is willing and able to provide written informed consent

        Exclusion Criteria:

          -  MCV value outside the reference range at screening

          -  Hemoglobin value at screening is: male subjects or post-menopausal females &gt; 15.5
             g/dL; female subjects &gt; 14.5 g/dL

          -  TIBC, serum iron and serum ferritin values are outside the reference range at
             screening

          -  Calculated creatinine clearance &lt; 60 ml/min

          -  Clinically significant abnormal CPK determined by the investigator and medical monitor

          -  AST, ALT and direct bilirubin are greater than upper limit of reference range at
             screening

          -  Subjects are unwilling or inability to follow the procedures and lifestyle and/or
             dietary restrictions outlined in the protocol

          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
             to the first dose of study medication, unless in the opinion of the Investigator and
             GSK Medical Monitor this will not interfere with the study procedures or compromise
             subject safety

          -  Subject currently exposures to more than four new chemical entities within 12 months
             prior to the first dosing day

          -  Use of other prescription or non-prescription drugs, vitamins, herbal and dietary
             supplements, within 7 days prior to the first dose of study medication

          -  Subject has a history of sensitivity to any of the study medications, or components
             thereof or a history of drug or other allergy

          -  Subjects with a pre-existing condition interfering with normal gastrointestinal
             anatomy or motility, hepatic and/or renal function, that could interfere with the
             absorption, metabolism, and/or excretion of the study drugs.

          -  Subject has a history of GI ulceration or gastrointestinal bleeding

          -  Subject has a history of peptic ulcer disease

          -  Subject has a history of malignancy tumor; non-melanoma skin cancer that has been
             definitely removed is allowed

          -  Treatment with an investigational drug within 30 days preceding the first dose of
             study medication

          -  Subjects with a history of drug abuse

          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of
             hard liquor) within 6 months of screening

          -  Positive urine drug screen (UDS) at screening

          -  Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result
             or positive HIV result within 3 months of screening

          -  Donation of blood in excess of 500 mL within 56 days prior to first dose of study
             medication

          -  Subject has a history of regular use of tobacco- or nicotine containing products

          -  History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to
             any of the study medications or components thereof
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/PHX111427?search=study&amp;search_terms=PHX111427#rs</url>
    <description>Results for study PHX111427 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerability</keyword>
  <keyword>Safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

